Why the study?
Dysfunctions in the renin-angiotensin system seem to be involved in the pathophysiology of mental illnesses, prompting assessment of RAS-related molecule levels in patients with bipolar disorder.
ACE levels should not guide bipolar management; cross-sectional data leave open biomarker utility pending longitudinal studies.
BACKGROUND: Dysfunctions in the renin-angiotensin system (RAS) seem to be involved in the pathophysiology of several mental illness, including schizophrenia and mood disorders. We carried out a cross-sectional study assessing the levels of RAS-related molecules among bipolar disorder (BD) patients compared to healthy controls. METHODS: our sample consisted of 30 outpatients with BD type 1 (10 males, 20 females, age = 35.53 ± 10.59 years, 14 euthymic, 16 experiencing mood episodes) and 30 healthy controls (10 males, 20 females, age = 34.83 ± 11.49 years). Plasma levels of angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), angiotensin-II (Ang II), and angiotensin (1-7) [Ang-(1-7)] were determined by ELISA. RESULTS: < 0.05). There was no association between the levels of these biomarkers and clinical parameters. CONCLUSION: Our findings support the involvement of RAS dysfunction in the pathophysiology of BD. Considering the potential therapeutic implications linked to a better understanding of the role of RAS dysfunction in BD, studies allowing a better characterization of RAS-related molecules level and activity across different mood states are of high interest.
No takes yet. Share an insight, caveat, or question.
Sanches et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: